Copenhagen Oe

• Dapagliflozin in Pulmonary Arterial Hypertension (DAPAH) Ended
  2024-518551-37-00 4 2023-01-01 Chronic thromboembolic pulmonary hypertension
• Study to assess safety and identify dose of ribociclib in combination of temozolomide and topotecan (TOTEM) in patients (12 months – 21 year … Ended
  2024-512095-35-00 9 2022-12-27 Relapsed or refractory neuroblastoma and other solid tumors (including
• Study of Nemvaleukin Alfa in Combination with Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients with Platinum-Resistant Ep … Ended
  2024-513230-38-00 5 2022-12-15 Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peri
• Phase 2 Randomized, Double-blind, Placebo-controlled Study of the Effect of EDG-5506 on Biomarkers in Adults with Neuromuscular Disease Ended
  2022-500215-39-00 4 2022-12-06 McArdle Disease
• A study in people with systemic sclerosis to test whether BI 685509 has an effect on lung function and other systemic sclerosis symptoms Ended
  2022-500332-11-00 4 2022-11-25 systemic sclerosis
• A Phase 3 study to determine the Efficacy and Safety of Losmapimod in Treating Patients with Facioscapulohumeral Muscular Dystrophy (REACH) Ended
  2024-512737-33-00 5 2022-09-30 Facioscapulohumeral Muscular Dystrophy (FSHD)
• TEMPLE - Thiopurine Enhanced Mutations for PD-1/​Ligand-1 Efficacy Ended
  2024-517307-37-00 7 2022-09-01 Oncology
• A Study of MK-1088 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors Ended
  2022-502288-40-00 4 2022-06-29 Treatment of advanced/metastatic solid tumors
• A Study Evaluating Bemarituzumab in Solid Tumors with FGFR2b Overexpression Ended
  2023-505455-44-00 9 2022-06-29 Solid tumours
• Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Ended
  2022-502773-41-00 9 2022-06-16 Relapsed/Refractory Classical Hodgkin Lymphoma
• A Phase 3 Study of Sotatercept in Newly Diagnosed Intermediate- and High-risk Pulmonary Arterial Hypertension (PAH) Patients. Ended
  2023-509139-16-00 5 2022-05-13 Therapeutic confirmatory (phase III)
• LOW-DOSE DOBUTAMINE INFUSION AND SINGLE-DOSE TOCILIZUMAB IN ACUTE MYOCARDIAL INFARCTION PATIENTS WITH HIGH RISK OF CARDIOGENIC SHOCK DEVELOP … Ended
  2024-515999-13-00 6 2022-03-13 Acute Myocardial Infarction with increased risk of Cardiogenic Shock
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination with Glofitamab in Participants wit … Ended
  2023-506699-29-00 3 2022-03-03 Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (r/r NHL)
• Study Comparing Bemarituzumab plus Chemotherapy with Placebo and Chemotherapy in Previously Untreated Advanced Gastric or Gastroesophageal J … Ended
  2023-505457-40-00 5 2022-02-02 Previously Untreated Advanced Gastric or Gastroesophageal Junction Can
• REPLACE - A multi-centre, randomised, double-blinded, placebo controlled 16-weeks study to compare the effect of hydrocortisone and placebo … Ended
  2024-513822-53-00 6 2022-02-01 Tertiary adrenal insufficiency
• An Phase 3 clinical study comparing a vector transferring the gene for Glucose-6-Phosphatase with placebo in adults with Glycogen Storage Di … Ended
  2023-508750-25-00 5 2022-01-11 Glycogen Storage Disease Type Ia (GSDIa)
• GEN1047 for Solid Tumors - First in Human (FIH) Trial Ended
  2024-510722-10-00 7 2021-12-13 Malignant Solid Tumors
• Phase II Study of efti plus pembrolizumab combination therapy for head and neck cancer (HNSCC). Ended
  2024-510762-16-00 4 2021-11-30 Metastatic head and neck squamous cell carcinoma (HNSCC)
• A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) Ended
  2022-500881-80-00 5 2021-10-29 Chronic Heart Failure With Reduced Ejection Fraction
• A trial to learn how well finerenone works and how safe it is in adult participants with non-diabetic chronic kidney disease Ended
  2023-506897-11-00 5 2021-10-18 Non-diabetic chronic kidney disease
• This study aims to find the best dose of BI 907828 (brigimadlin) in patients with different types of advanced cancer (solid tumors) Ended
  2024-511503-41-00 3 2021-08-13 Advanced or metastatic solid tumors
• Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal … Ended
  2022-501342-29-00 5 2021-07-21 Esophageal Carcinoma
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Inavolisib in Combination with Paclit … Ended
  2023-506745-33-00 3 2021-07-12 Locally Advanced or Metastatic Solid Tumors
• EASE SBS 3 (Evaluation of the efficacy and safety of Glepaglutide in the treatment of short bowel syndrome (SBS) Ended
  2024-513373-43-00 5 2021-06-11 Short bowel syndrome

Showing 601–624 of 671 trials